Clinical Trials Directory

Trials / Conditions / Metastatic Bladder Cancer

Metastatic Bladder Cancer

12 registered clinical trials studyying Metastatic Bladder Cancer1 currently recruiting.

StatusTrialSponsorPhase
RecruitingManagement of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessmen
NCT06138561
Dana-Farber Cancer Institute
UnknownStudy Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic
NCT05259319
Centre Georges Francois LeclercPhase 1
TerminatedTrilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy T
NCT04887831
G1 Therapeutics, Inc.Phase 2
Active Not RecruitingA Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
NCT06129084
Bernie Eigl
CompletedA Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva
NCT04200963
Ikena OncologyPhase 1
TerminatedA Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
NCT03498196
Baylor College of MedicinePhase 1 / Phase 2
CompletedEvaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carci
NCT03430895
Memorial Sloan Kettering Cancer CenterPhase 2
Active Not RecruitingA Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Blad
NCT02989584
Memorial Sloan Kettering Cancer CenterPhase 1 / Phase 2
CompletedDose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
NCT02030067
Processa PharmaceuticalsPhase 1 / Phase 2
UnknownThe Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel
NCT01814150
Gottfried Maya
CompletedPhase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
NCT02028442
Akamis BioPhase 1 / Phase 2
CompletedA Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
NCT01454089
Achieve Life SciencesPhase 2